Meeting
2011 ASCO Annual Meeting
Association between bone turnover markers and skeletal-related events in patients with breast cancer and bone metastases on treatment with bisphosphonates: ZOMAR study results at nine months of follow-up.
Authors
A. Barnadas
Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
A. Barnadas , C. De la Piedra , C. Crespo , P. Gomez Pardo , L. Calvo , E. G. Calvo , M. Ruiz-Borrego , J. Rifa , L. Manso , A. Anton , M. Codes , M. Margeli , A. Murias , J. Salvador , M. A. Seguí-Palmer , A. De Juan , J. Gavila , D. Perez , M. Luque , I. Tusquets
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 29: 2011 (suppl; abstr 594)
Abstract #
594
Poster Bd #
8D
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial.
First Author: Darya Kizub
Poster
2015 Genitourinary Cancers Symposium
Bone metabolism biomarkers in men with advanced prostate cancer (PC) and bone metastases treated with denosumab versus zoledronic acid (ZA).
First Author: Matthew Raymond Smith
Poster
2014 Palliative and Supportive Care in Oncology Symposium
A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study).
First Author: Carmel Maree Jacobs
Poster
2014 ASCO Annual Meeting
RANKL circulating levels in the evaluation of bone response in breast cancer (BC) patients.
First Author: Toni Ibrahim